0 13 Transcription Transcription NNP 14 20 factor factor NN 21 31 activation activation NN 32 34 in in IN 35 45 lymphokine lymphokine NN 46 55 activated activated JJ 56 62 killer killer NN 63 68 cells cell NNS 69 72 and and CC 73 84 lymphocytes lymphocyte NNS 85 89 from from IN 90 98 patients patient NNS 99 108 receiving receive VBG 109 113 IL-2 il-2 NN 114 127 immunotherapy immunotherapy NN 127 128 . . . 130 144 Administration Administration NNP 145 147 of of IN 148 151 the the DT 152 160 cytokine cytokine NN 161 174 interleukin-2 interleukin-2 NN 175 176 ( ( ( 176 180 IL-2 il-2 NN 180 181 ) ) ) 182 185 can can MD 186 192 result result VB 193 195 in in IN 196 207 therapeutic therapeutic JJ 208 216 benefits benefit NNS 217 220 for for IN 221 232 individuals individual NNS 233 237 with with IN 238 243 renal renal JJ 244 248 cell cell NN 249 258 carcinoma carcinoma NN 259 262 and and CC 263 271 melanoma melanoma NN 271 272 . . . 273 277 Here here RB 278 280 we we PRP 281 287 report report VBP 288 290 an an DT 291 299 analysis analysis NN 300 302 of of IN 303 306 the the DT 307 320 transcription transcription NN 321 327 factor factor NN 328 336 families family NNS 337 341 AP-1 ap-1 NN 341 342 , , , 343 346 Sp1 Sp1 NNP 346 347 , , , 348 357 NF-kappaB NF-kappaB NNP 357 358 , , , 359 362 and and CC 363 369 signal signal NN 370 381 transducers transducer NNS 382 385 and and CC 386 396 activators activator NNS 397 399 of of IN 400 413 transcription transcription NN 414 415 ( ( ( 415 419 STAT STAT NNP 419 420 ) ) ) 421 423 in in IN 424 430 cancer cancer NN 431 439 patients patient NNS 439 440 ’ ' POS 441 452 lymphocytes lymphocyte NNS 453 459 before before IN 460 463 and and CC 464 469 after after IN 470 474 IL-2 il-2 NN 475 488 immunotherapy immunotherapy NN 488 489 , , , 490 492 as as IN 493 501 assessed assess VBN 502 504 by by IN 505 506 a a DT 507 516 gel-shift gel-shift JJ 517 522 assay assay NN 522 523 . . . 524 526 An an DT 527 529 in in FW 530 535 vitro vitro FW 536 545 surrogate surrogate NN 546 548 of of IN 549 553 IL-2 il-2 NN 554 567 immunotherapy immunotherapy NN 568 570 is be VBZ 571 574 the the DT 575 585 incubation incubation NN 586 588 of of IN 589 594 fresh fresh JJ 595 605 peripheral peripheral JJ 606 611 blood blood NN 612 623 mononuclear mononuclear JJ 624 629 cells cell NNS 630 631 ( ( ( 631 635 PBMC PBMC NNP 635 636 ) ) ) 637 641 from from IN 642 649 healthy healthy JJ 650 661 individuals individual NNS 662 664 in in IN 665 669 IL-2 il-2 NN 670 673 for for IN 674 681 several several JJ 682 686 days day NNS 686 687 , , , 688 697 resulting result VBG 698 700 in in IN 701 704 the the DT 705 715 production production NN 716 718 of of IN 719 739 lymphokine-activated lymphokine-activated JJ 740 746 killer killer NN 747 748 ( ( ( 748 751 LAK LAK NNP 751 752 ) ) ) 753 761 activity activity NN 762 764 in in IN 765 770 these these DT 771 779 cultures culture NNS 779 780 . . . 781 784 One one CD 785 792 purpose purpose NN 793 795 of of IN 796 800 this this DT 801 806 study study NN 807 810 was be VBD 811 813 to to TO 814 822 describe describe VB 823 826 the the DT 827 834 profile profile NN 835 837 of of IN 838 851 transcription transcription NN 852 858 factor factor NN 859 869 activation activation NN 870 872 in in IN 873 878 these these DT 879 888 different different JJ 889 900 populations population NNS 900 901 , , , 902 905 and and CC 906 912 assess assess VB 913 920 whether whether IN 921 924 the the DT 925 933 patterns pattern NNS 934 942 observed observe VBN 943 953 correlated correlate VBD 954 958 with with IN 959 969 functional functional JJ 970 981 differences difference NNS 982 984 in in IN 985 990 these these DT 991 996 cells cell NNS 996 997 . . . 998 1003 Prior prior RB 1004 1006 to to TO 1007 1009 in in FW 1010 1014 vivo vivo FW 1015 1019 IL-2 il-2 NN 1020 1034 administration administration NN 1034 1035 , , , 1036 1039 the the DT 1040 1047 typical typical JJ 1048 1055 binding binding NN 1056 1063 pattern pattern NN 1064 1066 of of IN 1067 1080 transcription transcription NN 1081 1088 factors factor NNS 1089 1091 in in IN 1092 1096 PBMC PBMC NNP 1097 1101 from from IN 1102 1110 patients patient NNS 1111 1120 resembled resemble VBD 1121 1125 that that DT 1126 1130 seen see VBN 1131 1133 in in IN 1134 1139 fresh fresh JJ 1140 1144 PBMC PBMC NNP 1145 1149 from from IN 1150 1157 healthy healthy JJ 1158 1169 individuals individual NNS 1169 1170 . . . 1171 1175 Over over IN 1176 1177 a a DT 1178 1184 3-week 3-week JJ 1185 1191 course course NN 1192 1194 of of IN 1195 1199 IL-2 il-2 NN 1200 1207 therapy therapy NN 1207 1208 , , , 1209 1211 in in IN 1212 1216 most most JJS 1217 1225 patients patient NNS 1226 1229 the the DT 1230 1237 binding binding NN 1238 1246 patterns pattern NNS 1247 1249 of of IN 1250 1254 AP-1 ap-1 NN 1255 1256 , , , 1257 1260 Sp1 Sp1 NNP 1260 1261 , , , 1262 1265 and and CC 1266 1275 NF-kappaB NF-kappaB NNP 1276 1284 proteins protein NNS 1285 1292 changed change VBD 1293 1295 to to TO 1296 1304 resemble resemble VB 1305 1310 those those DT 1311 1315 seen see VBN 1316 1318 in in IN 1319 1323 PBMC PBMC NNP 1324 1333 activated activate VBN 1334 1336 by by IN 1337 1341 IL-2 il-2 NN 1342 1344 in in FW 1345 1350 vitro vitro FW 1350 1351 . . . 1352 1359 However however RB 1359 1360 , , , 1361 1364 the the DT 1365 1370 cells cell NNS 1371 1379 obtained obtain VBN 1380 1384 from from IN 1385 1397 IL-2-treated il-2-treated JJ 1398 1406 patients patient NNS 1407 1410 did do VBD 1411 1414 not not RB 1415 1419 have have VB 1420 1429 low-level low-level JJ 1430 1442 constitutive constitutive JJ 1443 1453 expression expression NN 1454 1456 of of IN 1457 1461 STAT STAT NNP 1462 1469 binding binding NN 1470 1477 factors factor NNS 1478 1480 as as IN 1481 1484 did do VBD 1485 1488 LAK LAK NNP 1489 1494 cells cell NNS 1494 1495 . . . 1496 1500 When when WRB 1501 1506 these these DT 1507 1514 patient patient NN 1515 1520 cells cell NNS 1521 1525 were be VBD 1526 1533 further further RB 1534 1544 stimulated stimulate VBN 1545 1547 by by IN 1548 1552 IL-2 il-2 NN 1553 1555 in in FW 1556 1561 vitro vitro FW 1561 1562 , , , 1563 1573 additional additional JJ 1574 1585 differences difference NNS 1586 1588 in in IN 1589 1593 STAT STAT NNP 1594 1603 induction induction NN 1604 1612 patterns pattern NNS 1613 1617 were be VBD 1618 1623 noted note VBN 1623 1624 . . . 1625 1630 These these DT 1631 1635 data datum NNS 1636 1643 provide provide VBP 1644 1651 further further JJ 1652 1663 information information NN 1664 1666 on on IN 1667 1670 the the DT 1671 1680 molecular molecular JJ 1681 1687 events event NNS 1688 1697 occurring occur VBG 1698 1700 in in IN 1701 1707 immune immune JJ 1708 1713 cells cell NNS 1714 1723 generated generate VBN 1724 1731 through through IN 1732 1734 in in FW 1735 1739 vivo vivo FW 1740 1743 and and CC 1744 1746 in in FW 1747 1752 vitro vitro FW 1753 1767 administration administration NN 1768 1770 of of IN 1771 1775 IL-2 il-2 NN 1775 1776 , , , 1777 1780 and and CC 1781 1788 further further JJ 1789 1797 document document NN 1798 1802 that that IN 1803 1808 there there EX 1809 1811 is be VBZ 1812 1815 not not RB 1816 1817 a a DT 1818 1825 precise precise JJ 1826 1836 congruence congruence NN 1837 1844 between between IN 1845 1849 PBMC PBMC NNP 1850 1859 activated activate VBN 1860 1862 in in FW 1863 1867 vivo vivo FW 1868 1871 and and CC 1872 1874 in in FW 1875 1880 vitro vitro FW 1881 1883 by by IN 1884 1888 IL-2 il-2 NN 1888 1889 . . .